Long-term management of deep vein thrombosis

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 6 SUPPL. 2, 1999, Pages

  Piovella, F ^a   Barone, M ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

Home therapy; Initial treatment; Low molecular weight heparins; Oral anticoagulants; Risk assessment; Secondary prophylaxis; Unfractionated heparin; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN ANTICOAGULANT; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLEEDING; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; THROMBECTOMY; THROMBOEMBOLISM; VENA CAVA FILTER;

COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; HUMANS; TIME FACTORS; VENOUS THROMBOSIS;

EID: 0032834633     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (44)

1. Anderson FA, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective on the incidence and case-fatality rates of venous thrombosis and pulmonary embolism, the Worcester DVT study. Arch Intern Med 1991; 151: 933-938.
2. Kierkegaard A. Incidence of acute DVT in two districts. A phlebographic study. Acta Chir Scand 1980; 146:267-269.
3. Ascari E, Siragusa S, Piovella F. The epidemiology of deep vein thrombosis and pulmonary embolism. Haemotologica 1995; 80 (suppl 2): 36-41.
4. Nicolaides AN, Bergqvist D, Hull R, Ackchurin RS, Allegra C, Arcelus J, et al. Consensus statement: prevention of venous thromboembolism. Int Angiol 1997; 16: 3-38.
5. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J Royal Soc Med 1989; 82: 203-205.
6. ten Cate JW, Koopman MMW, Prins MH, Buller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 74: 197-203.
7. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-462.
8. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-428.
9. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA 1994; 271: 223-225. [Erratum: JAMA 1994; 271: 1908]
10. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep vein thrombosis. JAMA 1994; 271: 223-225. [Erratum: JAMA 1994; 271: 1908]
11. Turkstra F, Kuijer PMM, van Beck EJR, Brandjes DP, ten Cate JW, Buller HR. Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med 1997; 12: 775-781.
12. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep vein thrombosis with low molecular weight heparins. A meta-analysis. Arch Intern Med 1995; 155: 601-607.
13. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-1828.
14. Hyers TM, Hull RH, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 95 (suppl); 408S-425S.
15. Hull RD, Raskob GE, Brant RF, Pinco GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157: 2562-2568.
16. A collaborative European Multicentre Study. A randomized trial of subcutaneous LMWH (CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1991; 65: 251-260.
17. Leizorovicz A. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep venous thrombosis. Drugs 1996; 52: 30-37.
18. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis. BMJ 1994; 309: 299-304.
19. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277.
20. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662.
21. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Laurent M, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.
22. The Enoxaparin Clinical Trial Group. A multicenter clinical trial comparing once-and twice-daily subcutaneous enoxaparin and intravenous heparin in the treatment of acute deep vein thrombosis. 39th Annual meeting and Exposition of the American Society of Hematology. San Diego, CA, USA. December 5-9, 1997, Abstract 1305.
23. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
24. Koopman M, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.
25. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264.
26. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulants therapy in the treatment of proximal vein thrombosis. N Engl J Med 1982; 307: 1676-1681.
27. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low-molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to courarin. Thromb Haemost 1994; 71: 7-11.
28. Hull R, Delmore T, Genton R, Hirsh J, Gent M, Sackett D, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
29. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-194.
30. Pini M, Alello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-197.
31. Holmgren K, Andersson G, Fagrell B, Johnsson H, Ljungberg B, Nilsson E, et al. One-month versus six-month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-284.
32. Levine MN, Hirsch J, Gent M, Turpie AGG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611.
33. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-876.
34. Schulman S, Rhedin A-S, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism, N Engl J Med 1995; 332: 1661-1665.
35. Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-398.
36. Hauch O, Khattar S, Jorgensen LN. Cost-benefit analysis of prophylaxis against deep vein thrombosis in surgery. Semin Thromb Hemost 1991; 17: 280-283.
37. Bergqvist D, Matzsch T. Cost/benefit aspects on thromboprophylaxis. Haemost 1993; 23 (suppl 1): 15-19
38. Detournay B, Planes A, Vochelle N, Fagnani F. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomis 1998; 13: 81-89.
39. Sarasin FP, Bounameaux H. Cost-effectiveness of prophylactic anticoagulation prolonged after hospital discharge following general surgery. Arch Surg 1996; 131: 694-697.
40. Gensini GF, Prisco D, Falciani M, Comeglio M, Colella A. Identification of candidates for prevention of venous thromboembolism. Semin Thromb Hemost 1997; 23: 55-67.
41. Chapuis Y, The Comité Scientifique Thrombose de l'AH-HP. Prophylaxie des thromboses veineuses postoperatoires: recommandations de l'Assistance publique-Hopitaux de Paris. Sang Thrombe Vaiss 1995; 7: 119-120.
42. THRIFT Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-574.
43. Clagett CP, Anderson FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108 (suppl): 312S-334S.
44. Agnelli G. Anticoagulation in the prevention and treatment of pulmonary embolism. Chest 1995; 107 (suppl 1): 39S-44S